Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Role of Peroxisome Proliferator Activated Receptor-delta in Leukaemia Immunotherapy
FY 2015-16
Summary
Cancer immunotherapy has the potential to cure many cancers but is often thwarted by the immunosuppressive nature of the target cells. A deeper knowledge of the mechanisms that facilitate immune escape would help point to strategies to boost the immunogenicity of cancer cells, ie. their ability to elicit immune responses, and improve the efficacy of immunotherapy. Aberrant lipid metabolism is a property of aggressive cancers that is associated with their ability to resist immune cells. We have found that the lipid activated nuclear receptor Peroxisome Proliferator Activated Receptor- d (PPARD) increases expression of immunosuppressive molecules such as STAT3 and IL10 in aggressive forms of Chronic Lymphocytic Leukemia (CLL), the commonest leukemia in the developed world. Based on these observations, we hypothesize that PPARD is a central regulator of immunosuppression and aim to study its regulatory activities and potential as a therapeutic target, using CLL as a clinical model. We will correlate PPARD expression and activities with immunogenic parameters of CLL cells and their ability to stimulate tumor-reactive T cells. We will also target PPARD with small-molecule inhibitors to determine if clearance of CLL cells can be enhanced in xenograft mouse models. We anticipate that PPARD levels will correlate with level of immunosuppression and blocking PPARD will boost immunogenicity. This study will help to improve immunotherapy for CLL that should apply to many other cancers.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
349896
Name
Xu An Qi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Role of Peroxisome Proliferator Activated Receptor-delta in Leukaemia Immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aberrant Lipid Metabolism; Chronic Lymphocytic Leukaemia; Leukemia Immunotherapy; Peroxisome Proliferator Activated Receptor-Delta
Abstract
Cancer immunotherapy has the potential to cure many cancers but is often thwarted by the immunosuppressive nature of the target cells. A deeper knowledge of the mechanisms that facilitate immune escape would help point to strategies to boost the immunogenicity of cancer cells, ie. their ability to elicit immune responses, and improve the efficacy of immunotherapy. Aberrant lipid metabolism is a property of aggressive cancers that is associated with their ability to resist immune cells. We have found that the lipid activated nuclear receptor Peroxisome Proliferator Activated Receptor- d (PPARD) increases expression of immunosuppressive molecules such as STAT3 and IL10 in aggressive forms of Chronic Lymphocytic Leukemia (CLL), the commonest leukemia in the developed world. Based on these observations, we hypothesize that PPARD is a central regulator of immunosuppression and aim to study its regulatory activities and potential as a therapeutic target, using CLL as a clinical model. We will correlate PPARD expression and activities with immunogenic parameters of CLL cells and their ability to stimulate tumor-reactive T cells. We will also target PPARD with small-molecule inhibitors to determine if clearance of CLL cells can be enhanced in xenograft mouse models. We anticipate that PPARD levels will correlate with level of immunosuppression and blocking PPARD will boost immunogenicity. This study will help to improve immunotherapy for CLL that should apply to many other cancers.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Xu, An Qi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~